Effect of a workplace-based group training programme combined with financial incentives on smoking cessation: a cluster-randomised controlled trial by Brand, F.A. van den et al.
www.thelancet.com/public-health   Vol 3   November 2018 e536
Articles
Effect of a workplace-based group training programme 
combined with financial incentives on smoking cessation: 
a cluster-randomised controlled trial 
Floor A van den Brand, Gera E Nagelhout, Bjorn Winkens, Niels H Chavannes, Onno C P van Schayck
Summary
Background Financial incentives are potentially useful tools to aid smoking cessation, but robust evidence to support 
their efficacy, particularly in combination with other interventions (eg, group counselling), has not been reported. We 
aimed to investigate whether financial incentives combined with a smoking cessation group training programme 
(compared with a training programme with no incentives) organised at the workplace would increase 12-month 
abstinence rates in tobacco-smoking employees with different education and income levels.
Methods This cluster-randomised controlled trial was done in the Netherlands with companies that offer a smoking 
cessation group training programme to all of their smoking employees. Eligible participants were tobacco-smoking 
employees and spouses of employees who were at least 18 years of age. Participants in the control group received a 
weekly 90-min session of smoking cessation group training for 7 weeks at the workplace; in addition to the group 
training, participants in the intervention group received vouchers for being abstinent (€50 at the end of the training 
programme, €50 3 months after completion of the programme, €50 after 6 months, and €200 after 12 months). 
Companies were randomly assigned by an independent research assistant to the intervention group or the control 
group with a digital randomisation programme, using a biased urn method. The primary outcome was carbon 
monoxide-validated continuous abstinence at 12 months. All randomised participants were included in the modified 
intention-to-treat analyses, with the exception of unavoidable loss (participants who had died or moved to an 
untraceable address (according to the Russell Standard), and in the sensitivity analyses, except the complete case 
analysis, which included only participants for whom all variables included in the model were not missing. This study 
is registered with the Dutch Trial Register, number NTR5657.
Findings Between March 1, 2016, and March 1, 2017, 61 companies with 604 participating smokers were enrolled. 
31 companies (319 smokers) were randomly assigned to the intervention group and 30 companies (285 smokers) to 
the control group. 12 months after finishing the smoking cessation programme, the proportion of individuals 
abstaining from smoking in the intervention group was significantly higher than that in the control group (131 [41%] 
of 319 vs 75 [26%] of 284; adjusted odds ratio 1·93, 95% CI 1·31–2·85, p=0·0009; adjusted for education level, income 
level, and Fagerström score). 
Interpretation Financial incentives in addition to a smoking cessation group training programme can significantly 
increase long-term smoking abstinence. The results of the current study could motivate employers to facilitate a 
workplace smoking cessation programme with financial incentives to help employees to quit smoking.
Funding Dutch Cancer Society.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 
license.
Introduction
Financial incentives can increase smoking cessation in 
diverse populations, with evidence showing moderate 
effects.1–4 However, the quality of this evidence is low 
because of inadequate randomisation and alloca tion 
procedures, deficient outcome reporting, and confound­
ing.2 Furthermore, the effectiveness of incentives is 
difficult to determine because of a wide range in type and 
size of the incentives. Additionally, previous studies2,3 were 
mainly done in the USA, which might limit generalisability. 
Finally, most studies5–7 have solely investigated the effect 
of incentives, without accompanying group counselling 
for smoking cessation. The effect of the combination of 
incentives with counselling is especially important to 
assess, considering evidence that group counselling can 
effectively enhance quit success.8
Previous studies provided an indication of which 
aspects of incentive­based programmes are effective. A 
study9 comparing different incentive schemes showed 
that reward­based incentive programmes (ie, smokers 
receive a reward) can possibly be more effective than 
deposit­based programmes (ie, smokers receive a refund 
of their own money deposit) in increasing smoking 
cessation, because of relatively high acceptance of 
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reward­based incentive programmes. Additionally, group 
counselling is more effective than self­help or less 
intensive help, such as brief support from a health­care 
provider.8
The workplace can be a constructive environment to 
stimulate tobacco cessation,10 and promotion of tobacco 
cessation is financially beneficial for employers. 
Employees who smoke tobacco show increased workplace 
absenteeism, loss of productivity due to smoking breaks 
or withdrawal symptoms, and increased health­care 
costs.11–13 Moreover, ex­smokers show decreased absentee­
ism and productivity losses compared with continuing 
smokers within 1–4 years.11 For employees, a smoking 
cessation training programme at the workplace is easily 
accessible, because it does not require a financial 
contribution, does not cost extra travel time, and is 
situated in a familiar environment. Furthermore, group 
counselling with colleagues can have an extra advantage 
of social support and peer pressure during and between 
counselling sessions.10,14
In the Netherlands in 2017, 23% of individuals aged 
18 years and older among the general population smoked 
on a regular basis.15 However, smoking prevalence is 
much higher among people with a low level of education 
(defined as elementary school and lower secondary 
education) in the Netherlands (29%) than among people 
with a high level of education (18%; defined as upper 
secondary education and university), and this difference 
in smoking prevalence is also found between people with 
lower and higher incomes.15 Smoking among employees 
strongly varies between work settings and can be 
substantially higher within certain companies.16 Since 
2004, by government decree, all employees are entitled to 
a smoke­free workplace and smoking in public places 
is prohibited; however, many companies have special 
rooms or cabins for smoking inside their building, or 
sheltered smoking areas on the company premises.
Although incentives for smoking cessation have been 
studied in different ways, these studies show modest quit 
rates at best. Although previous studies have shown 
evidence that reward­based incentives, group counselling, 
and workplace­situated interventions are effective,5,8,10 to 
our knowledge, no study has effectively combined these 
elements. The aim of the current study was to examine 
the effectiveness of a combination of these effective 
components within a cluster­randomised trial. We 
hypothesised that incentives in combination with a 
group smoking cessation training programme organised 
at the workplace would increase quit rates compared 
with a group training programme alone. A second aim 
was to investigate whether incentives might result in 
different cessation rates for employees with different 
levels of education, income, or nicotine dependency.
Methods
Study design
This study is a cluster­randomised controlled trial done 
in the Netherlands among companies that offer a 
Research in context
Evidence before this study
We searched PubMed and Google Scholar for research articles 
published in English using various search terms, including 
“financial incentives”, “incentives”, “monetary reward”, 
“smoking cessation”, “stop smoking”, “workplace”, “employers”, 
and “employees”. No date restrictions were used. We explored 
the Cochrane library and found a relevant review on incentives 
for smoking cessation, a review on workplace interventions for 
smoking cessation, and a review on group behaviour therapy 
programmes for smoking cessation. We also scanned reference 
lists of relevant papers to identify additional papers 
(snowballing). Previous reviews have shown a modest effect of 
incentives on quit rates, but the quality of the evidence was 
graded as low due to inadequate randomisation and allocation 
procedures, deficient outcome reporting, and confounding. 
Furthermore, most research has been done in the USA, and 
there is lack of evidence on the effect of incentives in a 
workplace setting outside the USA. Finally, some high-quality 
studies used solely incentives as an intervention, although a 
combination of incentives with a group cessation training 
programme might be more effective to help smokers quit.
Added value of this study
This study shows that financial incentives for smoking 
cessation in combination with a tobacco cessation group 
training programme can increase continuous abstinence 
compared with a group training programme alone. The current 
study shows a number needed to treat of seven for a single 
additional quitter, which shows that incentives combined with 
a smoking cessation group training programme are an effective 
treatment strategy compared with pharmacotherapy.
Implications of all the available evidence
Tobacco smoking is a major health threat, and more effective 
methods to decrease smoking are necessary. The current study 
adds evidence to the existing literature showing that incentives 
can help people to quit smoking. The biochemically validated 
smoking cessation rates in the current study of 41% after 
12 months have rarely been observed in the literature and 
indicate that this approach should be further investigated. 
Additionally, it is especially encouraging that the results show 
that incentives are effective for individuals with a low level of 
education and income, and might therefore be effective in 
decreasing the socioeconomic gap in smoking prevalence when 
specifically directed at this group. The current study shows that 
incentives in addition to an existing smoking cessation 
programme can increase quit rates, and whether incentives 
could also be used in other (health-care) settings to increase 
the effectiveness of existing smoking cessation programmes 
should be explored.
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smoking cessation group training programme to all of 
their smoking employees. The protocol of this study with 
a detailed description of the methods has been published17 
and can be consulted for additional information 
regarding research methods. The study protocol was 
approved by the Medical Research Ethics Committee of 
Atrium Medical Centre Heerlen, Heerlen, Netherlands 
(num ber 16­N­13).
Participants
We approached companies of varying size and from 
different industry types in the Netherlands to participate 
in this study by email and phone. Companies were 
required to facilitate a smoking cessation training 
programme at the workplace during or directly after 
working hours. Employees within participating companies 
were recruited by the company management using flyers, 
posters, email, and intranet messages, and spouses could 
also participate. Participants needed to be current tobacco 
smokers aged at least 18 years. Exclusion criteria were an 
acute life­threatening disease, not being a currently active 
smoker, not being able to read or speak Dutch, and having 
already started an attempt to quit smoking at the moment 
of inclusion. Before the start of the study, all participants 
were informed about the design of the study and the 
possibility to receive vouchers for quit success. All 
participants gave written informed consent. 
Randomisation and masking
Participants were randomly assigned on a cluster level to 
the intervention or control group. Participants from the 
intervention companies received financial incentives of up 
to €350 for successful smoking cessation, whereas 
participants from the control companies did not receive 
financial incentives. A cluster was defined as the assembly 
of participants within a company who followed the 
smoking cessation training programme together as a 
group. By cluster random isation, all participants within a 
group were allocated to the same (intervention or control) 
group to prevent possible feelings of unfairness. The 
randomisation sequence was generated by a digital 
programme using the biased urn method, in order to 
maintain allocation to intervention groups as balanced as 
possible.18 The randomisation programme was written by a 
statistician (BW), but companies were randomly allocated 
by an independent research assistant not involved in the 
study. Group allocation was not revealed to participants 
or employers until the start of the first training session.
Because of the nature of the intervention, it was 
not possible to mask the outcome assessor for the 
intervention groups. However, during the statistical 
analyses, which were first done at the 6­month follow­up 
and repeated at the 12­month follow­up, all researchers, 
including the statistician, were masked to treatment 
allocation. Allocation was unblinded after the first analyses 
were completed and the research team unanimously 
agreed on the interpretation of the findings.
Procedures
A smoking cessation group training programme was 
organised at each of the participating companies. The 
training programme consisted of a 90­min session per 
week for 7 weeks. The training sessions were given 
by professional coaches from the Dutch company 
SineFuma, which is experienced in giving smoking 
cessation group training in a workplace setting. The pre­
existing training programme was designed to help 
participants to initiate a quit attempt and guide them 
through the first few difficult weeks of quitting smoking, 
with an important role for group dynamics and peer 
support. Participants quit together at the start of the third 
session, and had quit smoking for about 1 month at the 
last session.
Intervention group (n=31) Control group (n=30)
Company size
0–50 2 (6%) 2 (7%)
51–100 2 (6%) 3 (10%)
101–200 3 (10%) 4 (13%)
201–500 8 (26%) 5 (17%)
501–1000 9 (29%) 4 (13%)
>1000 7 (23%) 12 (40%)
Industry type*
Administrative and support service activities 3 (10%) 0
Agriculture, forestry, and fishing 1 (3%) 0
Education 3 (10%) 1 (3%)
Financial and insurance activities 2 (6%) 2 (7%)
Human health and social work activities 4 (13%) 8 (27%)
Manufacturing 7 (23%) 9 (30%)
Mining and quarrying 1 (3%) 0
Professional, scientific, and technical activities 0 2 (7%)
Public administration and defence, and 
compulsory social security
2 (6%) 3 (10%)
Real-estate activities 0 1 (3%)
Transportation and storage 4 (13%) 2 (7%)
Water supply, sewerage, waste management, 
and remediation activities
1 (3%) 2 (7%)
Wholesale and retail trade 3 (10%) 0
Company smoking regulations†
Smoking is allowed
Yes 254/319 (80%) 236/285(83%)
No 51/319 (16%) 38/285 (13%)
Missing 14/319 (4%) 11/285 (4%) 
Employees can take a smoking break whenever 
they like
Yes 174/319 (55%) 188/285 (66%)
No 130/319 (41%) 86/285 (30%)
Missing 15/319 (5%) 11/285 (4%) 
Cluster size 10·6 (3·5) 10·4 (3·6)
Data are n (%) of companies, n/N (%) of employees, or mean (SD). *Based on the Standard Industrial Classification. 
†Based on self-report of individual employees, since possibilities to take a smoking break could vary depending on the 
type of job the employee had within a company. 
Table 1: Company characteristics
Articles
e539 www.thelancet.com/public-health   Vol 3   November 2018
Participants in the intervention group could earn 
four vouchers with a total worth of €350. The first 
€50 voucher was received on the condition of 
biochemically validated smoking abstinence at the end 
of the smoking cessation training programme. The 
second and third €50 vouchers could be earned when 
participants were abstinent 3 and 6 months after 
finishing the cessation programme. At the end of the 
study (12 months after completion of the cessation 
programme), participants could earn an additional 
€200 voucher.17 The value of the incentives was chosen 
to be high enough to motivate quitting smoking, while 
remaining acceptable for employers to implement in 
the future. The payment schedule was designed so that 
the first reward was received relatively soon (ie, directly 
after finishing the training) and so that the reward that 
was given after the longest period of abstinence 
(12 months) was the largest, to be attractive to the 
participants from the start of the intervention and 
taking into account the typical discounting of delayed 
rewards.19 The vouchers were sent by email in the form 
of a digital code that could be exchanged via a web shop 
for a large range of products or activities.
Outcomes
The primary outcome was 12­month carbon monoxide 
(CO)­validated continuous smoking abstinence according 
to the Russell Standard.20 Smoking abstinence was 
assessed by self­report of continuous abstinence, 
biochemically validated by CO measurement. Secondary 
outcomes were CO­validated smoking abstinence and 
self­reported abstinence directly after completing the 
smoking cessation training programme, after 3 months, 
and after 6 months. A PiCO Smokerlyzer (Bedfont 
Scientific, Kent, UK) was used to measure expired­air CO 
concentrations, with a cutoff point of 9 parts per million.20 
In case of disagreement between participants’ self­report 
of smoking and CO measurement, participants were 
classified as smokers. Missing values on self­reported 
smoking and missing CO validation on endpoint measure­
ments were counted as smokers. That is, if an individual 
self­reported or was found to be smoking at 3 or 6 months 
but was abstinent at the 12­month visit, they would not 
receive the €200 financial incentive and would not be 
classified has having met the primary endpoint.
We used a baseline questionnaire to assess participant 
characteristics. Participants were asked to state their 
highest completed education, which was recoded into 
three categories: low (none completed, primary school 
and lower secondary education), moderate (middle 
secondary education) and high (upper secondary 
education and university). We assessed net monthly 
household income with a multiple­choice item with 
13 categories. Income was individualised for each 
participant by taking the mean of the lower and upper 
boundary of each household income category and 
dividing this amount by the square root of the number of 
people in the household.21 The individualised income 
was divided into three categories based on tertiles. 
Furthermore, we assessed whether participants had 
attempted to quit smoking in the past (yes or no), 
and how many cigarettes on average they smoked per 
day. We calculated pack­years to assess life­time smoking 
and we measured nicotine dependence with the 
Fagerström Nicotine Addiction questionnaire, in which 
a scale from 1 (not addicted) to 10 (heavily addicted) 
determines the level of nicotine addiction.22
Statistical analysis
Estimates for the sample size calculation were based on a 
previous study with 15% quitters in the intervention group 
versus 5% in the control group.5 With an alpha of 0·05 
and 80% power to detect this effect, a sample size of 
Figure 1: Trial profile
61 clusters (694 smokers) were contacted
61 clusters (604 smokers) randomised
4 individuals did not meet inclusion criteria
50 were not able or did not want to participate
36 did not return signed consent form
30 clusters (285 smokers) allocated to control 
group 
285 smokers assessed after training 
programme
2 withdrew 
283 assessed at 3 months
2 lost to follow-up
3 withdrew 
278 assessed at 6 months
3 lost to follow-up 
2 withdrew 
273 assessed at 12 months
284 included in intention-to-treat analysis
6 lost to follow-up 
3 withdrew 
31 clusters (319 smokers) allocated to 
intervention group 
319 smokers assessed after training 
programme
3 withdrew 
316 assessed at 3 months
2 lost to follow-up
2 withdrew 
312 assessed at 6 months
2 lost to follow-up 
310 assessed at 12 months
319 included in intention-to-treat analysis
3 lost to follow-up 
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141 participants per group was required. Considering the 
cluster­randomised design and assuming a mean 
of 12 participants per cluster (m), and an intra­class 
correlation (ICC) of 0·05,23 the design effect [=1 + (m−1)
ICC] equalled 1·55, which yielded a sample size of 
219 participants per group. Taking into account 15% loss to 
follow­up due to unexpected employee turnover,5 at least 
516 participants within at least 44 clusters needed 
to be included in the study. We present participant 
characteristics using frequencies (%) for categorical 
variables and means (SDs) for numerical variables. In the 
modified intention­to­treat analysis, all randomly assigned 
participants were included in the denominator for cal­
culating abstinence with the exception of unavoidable loss 
(participants who had died or moved to an untraceable 
address), as stated in the Russell Standard.20 We assessed 
the difference in continuous smoking abstinence (within 
1, 3, 6, or 12 months) between the intervention group and 
the control group using a generalised linear mixed­effects 
model analysis with a logit link (binary outcome) and a 
random intercept at the company level to adjust for the 
clustering of participants within a company. The fixed part 
of the model included group (intervention vs control) and 
prespecified variables known to be related to the outcome: 
income (three categories), education (three categories), 
and nicotine dependency (Fagerström score). We imputed 
missing data on these variables using the other fixed 
variables that were included in the model, and used sex, 
company, number of attended sessions (0–7), and 
continuous abstinence as predictors. We used multiple 
imputation to create 50 complete datasets, where the 
maximum number of iterations was set to 20 and trace 
lines were used to check convergence. We used the 
complete case analysis (including only participants for 
whom all variables included in the model were not 
missing), as well as the model that only included group as 
the fixed factor (no correction for other variables), as 
sensitivity analyses. We investigated the possible effect 
modification of income, educational level, and nicotine 
dependency (Fagerström score) by including these factors 
as interactions with group in the model. Two­sided p values 
of 0·05 or less were considered statistically significant. We 
used IBM SPSS Statistics for Windows (version 23.0) to 
compute descriptive statistics. We used the RStudio 
version 1.1.383 mice package for multiple imputation and 
lme4 package (glmer function) for the generalised linear 
mixed­effects models. 
The trial is registered at the Dutch Trial Register, 
number NTR5657.
Role of the funding source
The funder had no role in the study design, the collection 
or analysis of the data, the interpretation of data, the 
writing of the report, or the decision to submit the article 
for publication. The corresponding author had full access 
to all of the data and the final responsibility to submit for 
publication.
Results
61 companies were recruited from March 1, 2016, to 
March 1, 2017 (table 1). 694 smokers were contacted, of 
whom four did not meet the inclusion criteria, 50 were 
not able or did not want to participate in the study, and 
36 did not provide a signed informed consent form 
(figure 1). The remaining 604 participants (of whom one 
was a spouse) were randomly assigned to the control 
group (30 clusters, 285 participants) or the intervention 
group (31 clusters, 319 participants), and used as the 
Intervention group (n=319) Control group (n=285)
Age, years 43·9 (10·4) 46·6 (9·7)
Sex
Women 102 (32%) 121 (42%)
Men 217 (68%) 164 (58%)
Educational level
Low 97 (30%) 62 (22%)
Middle 136 (43%) 119 (42%)
High 75 (24%) 90 (32%)
Missing 11 (3%) 14 (5%)
Income level
Low 111 (35%) 68 (24%)
Middle 91 (29%) 84 (29%)
High 76 (24%) 105 (37%)
Missing 41 (13%) 28 (10%)
Attempted to quit in the past
Yes 253 (79%) 228 (80%)
No 55 (17%) 48 (17%)
Missing 11 (3%) 9 (3%) 
Cigarettes per day
≤10 58 (18%) 55 (19%)
11–20 179 (56%) 159 (56%)
21–30 59 (18%) 58 (20%)
≥31 9 (3%) 3 (1%)
Missing 14 (4%) 10 (4%)
Pack-years 21·6 (13·2) 23·5 (13·0) 
Missing 24 (8%) 11 (4%)
Fagerström test for nicotine dependence 4·4 (1·9) 4·5 (2·0)
Missing 19 (6%) 12 (4%)
Used nicotine replacement therapy during quit attempt
Yes 134 (42%) 130 (46%)
No 156 (49%) 117 (41%)
Missing 29 (9%) 38 (13%) 
Used medications* during quit attempt
Yes 77 (24%) 43 (15%)
No 212 (66%) 204 (72%)
Missing 30 (9%) 38 (13%)
Used e-cigarettes during quit attempt
Yes 52 (16%) 58 (20%)
No 235 (74%) 184 (65%)
Missing 32 (10%) 43 (15%)
Data are mean (SD) or n (%). *Varenicline, bupropion, or other smoking cessation medications. 
Table 2: Participant baseline characteristics 
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denominator in all analyses according to the modified 
intention­to­treat protocol, with the exception of the 
biochemically validated outcome at 12 months, where 
one participant from the control group was excluded 
from the analysis because of unavoidable loss to follow­
up (figure 1). The mean age of the participants was 
45 years (SD 10·17), and the majority were men (table 2). 
481 (80%) of 604 participants reported having tried to 
quit in the past (table 2). Participants reported a mean of 
22 pack­years (SD 13·17) and a mean Fagerström score of 
4·4 (1·98; table 2). The mean net annual individualised 
house hold income in our study was €24 170·97 (SD 
8788·53; appendix), which makes the €350 incentive 
1·45% of the participants’ average annual household 
income.
The smoking cessation training programme consisted 
of seven sessions, of which participants attended a mean 
of 5·5 sessions (SD 1·6) in the control group and a mean 
of 5·8 sessions (1·4) in the intervention group (appendix). 
Participants from both groups who were abstinent from 
smoking at 12 months after the training programme had 
attended, on average, about one session more than 
participants who had relapsed to smoking.
In all cases in which participants self­reported that 
they were abstinent and CO verification was done, 
the CO score confirmed the participants’ self­report 
(figure 2; table 3). For the primary outcome at 12 months, 
131 (41%) of 319 participants in the intervention group 
and 75 (26%) of 284 participants in the control group were 
verified quitters (adjusted odds ratio [OR] 1·93, 95% CI 
1·31–2·85; p=0·0009; table 3). Directly after completion 
of the smoking cessation training programme, 266 (83%) 
of 319 participants in the intervention group and 216 
(76%) of 285 participants in the control group were 
verified quitters (adjusted OR 1·77, 95% CI 1·00–3·12; 
p=0·050; table 3). At 3 months, the proportion of quitters 
was 172 (54%) of 319 in the intervention group and 
125 (44%) of 285 in the control group (adjusted OR 1·55, 
95% CI 1·07 to 2·24; p=0·021; table 3). At 6 months, the 
difference in the proportion of participants who were 
abstinent between the intervention group and control 
group increased to 19% (adjusted OR 2·39, 95% CI 
1·62–3·52; p<0·0001; table 3).
The analyses investigating possible effect modification 
of income, education, or nicotine dependency showed no 
significant interactions (all p values ≥0·079; appendix), 
indicating similar effects for these subgroups. The 
results for the lowest income and education groups 
show similar patterns to the whole group; that is, an 
inter vention effect was obtained after 6 months (table 4).
In the sensitivity analysis (appendix) in which only 
study group was included as the fixed factor, with no 
correction for other variables, ORs and corresponding 
p values were in the same direction and of similar 
magnitude as in the main analysis. The results of the 
adjusted (n=507) complete case analysis that included 
only participants for whom none of the variables in the 
model were missing also showed results similar in size 
and direction to those of the main analysis (12­month 
CO­validated abstinence complete case analysis OR 2·14; 
main analysis OR 1·93; appendix). The intra­class 
correlation in the CO­validated adjusted complete case 
analysis was 0·043 for the 12­month measurement point 
(appendix).
Discussion
In this cluster­randomised controlled trial, we aimed to 
determine whether financial incentives in addition to a 
smoking cessation group training programme (compared 
with a training programme with no incentives) was 
Figure 2: Validated smoking abstinence in the intervention vs control groups
Figure shows histogram of modified intention-to-treat analysis with multiple imputation, adjusted for education 
level, income level, and Fagerström score, with percentages of validated abstinence in the intervention (smoking 
cessation programme plus financial incentive) and control (smoking cessation programme only) groups directly 
after the smoking cessation training programme, at 3 months, 6 months, and 12 months. Δ=risk difference.
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Intervention 
group 
(n=319)
Control 
group 
(n=285)
Adjusted odds 
ratio* (95% CI)
p value Number 
needed to 
treat for one 
abstinent 
smoker
Abstinence after programme 
completion 
·· ·· ·· ·· 13
Self-reported 267 (84%) 226 (79%) 1·50 (0·81–2·75) 0·195 ··
Biochemically validated 266 (83%) 216 (76%) 1·77 (1·00–3·12) 0·050 ··
3-month abstinence ·· ·· ·· ·· 10
Self-reported 181 (57%) 137 (48%) 1·46 (1·00 –2·15) 0·051 ··
Biochemically validated 172 (54%) 125 (44%) 1·55 (1·07–2·24) 0·021 ··
6-month abstinence ·· ·· ·· ·· 5
Self-reported 149 (47%) 95 (33%) 1·78 (1·21–2·64) 0·0039 ··
Biochemically validated 145 (45%) 76 (27%) 2·39 (1·62–3·52) <0·0001 ··
12-month abstinence ·· ·· ·· ·· 7
Self-reported 132 (41%) 80 (28%) 1·81 (1·24–2·65) 0·0022 ··
Biochemically validated 131 (41%) 75/284 
(26%)†
1·93 (1·31–2·85) 0·0009 ··
Data are n (%) or n/N (%). Modified intention-to-treat analysis with multiple imputation. *Adjusted for education 
level, income level, and Fagerström score. †One participant excluded from the analysis because of unavoidable loss to 
follow-up according to the Russell Standard. 
Table 3: Continuous abstinence at endpoints
See Online for appendix
Articles
www.thelancet.com/public-health   Vol 3   November 2018 e542
effective in increasing abstinence in tobacco­smoking 
employees. Our findings show that financial incentives 
for abstinence in combination with a tobacco cessation 
group training programme at the workplace stimulate 
smoking cessation and are effective in smokers with a 
low level of education and income. Incentives can 
increase the number of successful quitters compared 
with a group training programme alone. 
Incentives significantly increased 12­month continuous 
abstinence, with validated quit percentages of 41% in the 
intervention group with 26% in the control group. In 
two similar, large studies5,7 that investigated incentives 
for smoking cessation within companies, 12­month quit 
rates were considerably lower than in the current study. 
In one of those studies,5 12­month quit rates were 9·4% 
in the incentive group and 3·6% in the control group, 
even though the amount of money used as an incentive 
in that study (US$750) was considerably higher than in 
the current study (€350, which is approximately $410). 
Although participants in that study5 were encouraged 
with a $100 incentive to seek smoking cessation 
counselling, counselling was not a standard part of the 
protocol, and few people participated in a counselling 
programme (15·4% in the incentive group and 5·4% in 
the control group). Therefore, the higher quit rates 
observed in the current study than in other workplace­
based incentive studies5,7 might be explained by the 
addition of  the smoking cessation programme, in which 
all participants of the current study were enrolled. 
Although the current study was not designed to assess 
the effectiveness of the training programme, and quit 
success might also result from factors outside the 
training programme, motivation to quit smoking elicited 
by the incentive is likely to increase quit success if 
smokers are supported in a professional group training 
programme that increases knowledge and skills, provides 
social support, and removes barriers to quitting. This 
notion is supported by the observation that, in the current 
study, the control group (no incentives) also showed high 
quit rates at 3 months (44%), while in the control group 
of the study by Volpp and colleagues5 only 11·8% of 
participants were abstinent at the first measurement. 
These numbers might reflect the effectiveness of a 
comprehensive group training programme with multiple 
sessions, as was used in the current study, and are in line 
with earlier research that showed the value of smoking 
cessation counselling and its contribution to successful 
quitting.8,24 Another similar study done in Switzerland 
investigated the effect of large incentives up to $1650 
(without counselling) for 12­month abstinence.6 The 
results showed 12­month abstinence rates of 9·5% in the 
incentive group (and 3·7% in the control group). The 
current study used much smaller incentives but had 
higher quit rates than the study of Etter and Schmid,6 
which suggests that modest incentives might have the 
potential to be as effective as large incentives if combined 
with additional smoking cessation support.
This study showed that the effect of incentives on 
smoking abstinence was similar among smokers with 
high, medium, and low levels of education and income, 
indicating that the intervention was effective even for the 
low income and education groups. This result is 
important, because smokers with low socioeconomic 
status are less likely to quit,25 and many existing smoking 
cessation interventions are more effective among those 
from higher socio economic status groups,26 which leads 
to increasing differences in smoking prevalence.27 
Therefore, financial incentives for smokers with low 
socioeconomic status could be an effective strategy to 
decrease the socio economic gap in smoking.
Although most participants in this study were initially 
successful in quitting smoking during the smoking 
cessation training programme, quit rates rapidly declined 
within the first 3 months after the training programme 
had finished. Steep relapse curves are also found in 
smokers who quit without assistance, where most relapses 
occur in the first 8 days of a quit attempt.28 The results 
showed that the proportion of participants who were 
abstinent remained fairly stable between the 6 and 
12 months of follow­up in both groups, which is in line 
with research suggesting that the risk of relapse declines to 
almost zero after 100 days of continuous abstinence.29 
Importantly, in the present study, the difference in 
abstinence between the intervention and control group 
increased over time (from about 8% to about 15%), which 
shows that incentives are not only effective in motivating 
initial quit attempts, but can also be a crucial factor for 
sustained abstinence. The results of this study suggest that 
professional support can help to lengthen a quit attempt, 
but raises the question about whether smoking cessation 
guidance should be extended to a longer period, with, for 
example, a refresher session within the first 6 months after 
finishing the smoking cessation programme. The right 
Adjusted odds 
ratio* (95% CI)
p value
Abstinence after programme completion
Low education 1·45 (0·58–3·65) 0·428
Low income 1·27 (0·54–2·96) 0·582
3-month abstinence 
Low education 1·54 (0·77–3·07) 0·219
Low income 1·96 (1·04–3·73) 0·039
6-month abstinence
Low education 3·84 (1·81–8·12) 0·0005
Low income 3·99 (1·90–8·38) 0·0003
12-month abstinence 
Low education 2·71 (1·28–5·70) 0·0091
Low income 1·90 (0·96–3·74) 0·064
159 participants had a low level of education and 179 participants had a low 
income. *Adjusted for education level, income level, and Fagerström score. 
Table 4: Analyses for biochemically validated continuous abstinence for 
participants with a low level of education and low income
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incentive size and timing of delivery might flatten the 
relapse curve, but research in this area is scarce.2,30,31 
Therefore, future studies should determine the optimal 
size and timing of incentives to facilitate quitting, by 
varying incentive schemes and amounts.
The current study has some limitations that should be 
taken into consideration. Although this study was 
executed within a large number of diverse companies, 
the results might not be generalisable to every company, 
since employee characteristics might affect outcomes.16 
Participants volunteered to follow the smoking cessation 
training programme and were therefore assumed to be 
motivated and ready to quit. Participants in the control 
group were not masked to the intervention condition of 
receiving vouchers for quit success. This had the 
advantage that both groups could be recruited with an 
identical strategy, which prevented selection bias between 
the intervention and control group while using the 
incentives to increase enrolment.32 However, this might 
have led to disappointment or loss of motivation when 
the randomisation result was revealed during the first 
training session. However, only a small number of 
participants withdrew from the study in either study 
group. Furthermore, the mean number of training 
sessions attended was similar between the intervention 
and control groups, with a small (but significant) 
difference (5·8 vs 5·5 sessions). This difference might 
have been caused by a mediating effect of the incentives; 
for example, the incentives might have increased the 
participant’s motivation to be present at the training 
sessions. Another limitation of the current study was 
that these results show quit rates while the incentives 
were still in place. More research is needed to determine 
whether incentives also contribute to long­term smoking 
cessation when the incentives are removed.2 Although a 
considerable effort was made to verify each self­reported 
quitter with biochemical testing (eg, by making extra 
company visits and scheduling home appointments) 
CO verification could not be done for every participant. 
This was mostly caused by scheduling problems, 
vacations, or illness. According to protocol, the 
participants were included as smokers in the analysis. 
Since participants in the intervention group could have 
been more willing to attend the CO measurement 
appointments in order to receive the incentive, this could 
explain the small difference between self­reported and 
biochemically validated quit rates. In the current study, 
expired air CO measurement was chosen as biochemical 
verification. Although CO is the preferred method to 
detect recent smoking,20 there is no objective way of 
verifying abstinence over the full 12 months. A particular 
concern with incentive­based trials is that the opportunity 
to receive a reward in combination with the relatively 
short detection period of CO measurement might enable 
gaming (in which participants deliberately mislead study 
investigators about their smoking behaviour to obtain 
financial incentives). A previous study33 involving 
financial incentives for smoking cessation in pregnant 
women that investigated gaming by comparing smoking 
abstinence based on self­report and CO measurement 
with cotinine measurement found that only 4% of 
participants showed false reporting of smoking status. 
Although gaming in the current study cannot be 
ruled out completely, the fact that there were no 
CO measurements that did not correspond with the 
participant’s self­report of abstinence strengthens 
confidence in the results. Notably, three participants who 
at first claimed to be abstinent, upon further inquiry, 
turned out to have a different definition of abstinence 
from the research criteria; all participants had quit 
smoking cigarettes, but one participant still smoked 
cigars, another smoked marijuana, and the third used a 
hookah to smoke tobacco. This shows that it is important 
to clarify what is considered as tobacco smoking when 
assessing self­report of smoking.
The results of the current study could have implications 
for current tobacco cessation treatment methods. 
Previous research has shown that proof of effectiveness 
of incentives is an important contributor to the 
acceptability of incentives for quitting smoking.34,35 The 
results of the current study might therefore increase 
support for this relatively new strategy to decrease 
smoking. The number needed to treat for a single 
additional quitter during at least 12 months in the current 
study was seven (table 3), which shows that incentives 
are a very effective treatment strategy, whereas previous 
research showed less favourable numbers need to treat 
for a single additional quitter in case of pharmacotherapy 
(number needed to treat for varenicline was ten, for 
bupropion 18, and 23 for nicotine replacement therapy).36 
This study showed that modest incentives can elicit 
substantial quit success. The results of the current study 
might therefore motivate employers to facilitate a 
smoking cessation programme combined with incentives 
at the workplace to help employees to quit smoking.
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